参考文献:1. Anderson DC, Kodukula K (2014) Biomarkers in pharmacology and drug discovery. Biochem Pharmacol 87:172-88 CrossRef 2. Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483:531-33 CrossRef 3. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafo MR (2013) Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14:365-76 CrossRef 4. Chalmers I, Glasziou P (2009) Avoidable waste in the production and reporting of research evidence. Lancet 374:86-9 CrossRef 5. Cyranoski D (2013) China drugs head fired over article row. Nature 498:283 CrossRef 6. Fang FC, Steen RG, Casadevall A (2012) Misconduct accounts for the majority of retracted publications. Proc Natl Acad Sci USA 109:17028-7033 7. Fanelli D (2009) How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS One 4:e5738 CrossRef 8. Fitz NF, Cronican AA, Lefterov I, Koldamova R (2013) Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models- Science 340:924 CrossRef 9. Franco A, Malhotra N, Simonovits G (2014) Publication bias in the social sciences: unlocking the file drawer. Science 345:1502-505 CrossRef 10. Frantz S (2004) Therapeutic area influences drug development costs. Nat Rev Drug Disc 3:466-67 CrossRef 11. Ioannidis JPA (2005) Why most published research findings are false. PLoS Med 2:e124 CrossRef 12. Ioannidis JPA (2014) How to make more published research true. PLoS Med 11:e1001747 CrossRef 13. Kilkenny C, Parsons N, Kadyszewski E, Festing MFW, Cuthill IC, Fry D, Hutton J, Altman DG (2009) Survey of the quality of experimental design, statistical analysis and experimental reporting of research using animals. PLoS One 11:e7824 CrossRef 14. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Disc 3:711-15 CrossRef 15. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490:187-91 CrossRef 16. Lazzeroni LC, Lu Y, Belitskaya-Levy I (2014) P-values in genomics: apparent precision masks high uncertainty. Mol Psychiatry. doi:10.1038/mp.2013.184 17. Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Khan AW, Glasziou P (2014) Biomedical research: increasing value, reducing waste. Lancet 383:101-04 CrossRef 18. McNutt M (2014) Journals unite for reproducibility. Science 346:678 19. Mehta J (2011) Preclinical Outsourcing Report: Long-term and more collaborative contracts to optimize cost structures. Contract Pha
刊物类别:Biomedical and Life Sciences
刊物主题:Biomedicine Pharmacology and Toxicology Psychiatry